SPOTLIGHT -
Dr. Essel Discusses Adverse Events of Bevacizumab in Ovarian Cancer
Kathleen Essel, MD, fellow, University of Oklahoma Health Science Center, discusses adverse events with bevacizumab (Avastin) in ovarian cancer.
Read More
Dr. Essel Discusses Long-Term Bevacizumab in Ovarian Cancer
Kathleen Essel, MD, fellow, University of Oklahoma Health Science Center, discusses a study on the effects of long-term bevacizumab (Avastin) use in patients with ovarian cancer.
Dr Berkenstock on ADC-Related Ocular Toxicities in Cervical and Ovarian Cancers
Dr Matalonis on the Management of Mirvetuximab Soravtansine-Related Toxicities in FRα+ Ovarian Cancer
Updated EMPOWER-Lung 3 Data Support Frontline Cemiplimab Plus Chemo in Advanced NSCLC
Neoadjuvant Nivolumab Plus Chemotherapy Retains EFS Advantage in Resectable NSCLC
